Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Very Bearish -75

Charles River Laboratories International Q1 Earnings Call Highlights

AI-generated analysis

📅 Charles River Laboratories (CRL) reported first-quarter 2026 results that slightly outperformed its prior outlook under new CEO Birgit Girshick.

🎯 CEO Birgit Girshick introduced a refreshed strategic framework titled "Pathway to Purpose" focused on modernization, portfolio strength, and improved profitability.

💰 Reported Q1 revenue reached $996 million, a 1.2% year-over-year increase, while organic revenue declined by 1.5%.

📉 Non-GAAP operating margins contracted 280 basis points to 16.3%, driven by lower NHP third-party revenue and higher sourcing costs.

🔧 The CFO attributed the margin decline to CEO transition stock compensation expenses and unfavorable timing of NHP shipments in specific segments.

🔄 The company repurchased approximately $200 million in shares during the quarter under its existing $1 billion authorization program.

📊 Discovery and Safety Assessment segment revenue fell 1.4% organically, with discovery services down partly due to prior site consolidation.

🦮 Research Models and Services revenue dropped 5.5% organically, pressured by lower North American small model volumes despite solid growth in China.

🧪 Manufacturing segment showed strength with organic revenue up 2.9%, driven by growth in the Microbial Solutions business.

📈 Q1 EPS declined 12% to $2.06 on a non-GAAP basis but exceeded guidance for the high-teens decline range.

🤝 Charles River reaffirmed its full-year 2026 guidance, expecting organic revenue decline of 0.5% to 1.5% and EPS between $10.80 and $11.30.

💸 Management noted a 50 basis point reduction in reported revenue outlook due to strengthening U.S. dollar foreign exchange headwinds.

🗓️ The company expects operating margin expansion of 120 to 150 basis points in 2026, with the majority occurring in the second half of the year.

🏷️ For Q2, reported revenue is expected to decline at a mid- to high-single-digit rate primarily due to ongoing divestitures.

📉 Second-quarter organic revenue is projected to decline at a low-single-digit rate, consistent with the first quarter performance.

💹 Q2 EPS is forecasted to increase by at least 30% sequentially from the first-quarter level of $2.06.

💼 Charles River completed the divestiture of its CDMO and Cell Solutions businesses on May 6 to refine its portfolio toward core competencies.

🏭 The company plans to complete the sale of certain European discovery sites later in May to further improve operating margins.

🇰🇭 Charles River acquired assets from K.F. Cambodia earlier this year to strengthen and secure its NHP supply chain for safety assessment operations.

Bullish Signals
  • Management reaffirmed full-year organic revenue and non-GAAP earnings guidance for 2026, demonstrating confidence in the strategic direction under new CEO Birgit Girshick.
  • Manufacturing segment reported positive growth with organic revenue up 2.9% and operating margin expanding 280 basis points to 25.9%, driven by strong performance in Microbial Solutions businesses like Endosafe and Celsis.
  • Charles River repurchased approximately $200 million of shares during the quarter, strengthening balance sheet under a $1 billion authorization approved last October.
  • Management expects operating margin expansion of about 120 to 150 basis points in 2026, with second-half operating margins projected to be more than 500 basis points higher than the first half.
  • Second-quarter earnings per share are expected to increase at least 30% sequentially from Q1, signaling strong profitability improvements despite modest revenue declines.
  • The company successfully completed the divestiture of its CDMO and Cell Solutions businesses on May 6, refining its portfolio around core competencies to improve future margins.
  • Charles River strengthened its NHP supply chain by acquiring assets from K.F. Cambodia for safety assessment operations, supported by its earlier controlling stake acquisition in Noveprim.
  • EPS exceeded management's prior outlook for a high-teens decline due to better-than-expected operating performance in the Manufacturing and Research Models and Services segments.
Risk Factors
  • First-quarter revenue declined 1.5% on an organic basis, consistent with prior forecasts of a low single-digit decline.
  • Non-GAAP operating margins contracted 280 basis points year over year to 16.3%, driven by higher NHP sourcing costs and unfavorable revenue mix.
  • Non-GAAP earnings per share fell 12% to $2.06, signaling significant pressure on profitability despite management guidance being met.
  • Discovery and Safety Assessment segment revenue dropped 1.4% organically due to lower discovery services and higher study-related direct costs.
  • Research Models and Services revenue decreased 5.5% organically, pressured by lower North American small model volume and unfavorable NHP shipment timing.
  • Charles River reduced its full-year 2026 revenue outlook by an additional 50 basis points to a decline of 4.0% to 5.5% due to a strengthening U.S. dollar.
  • Second-quarter reported revenue is expected to decline at a mid- to high-single-digit rate, primarily driven by completed divestitures including the CDMO and Cell Solutions businesses sold on May 6.
  • Non-human primate (NHP) segment faces specific headwinds from increased sourcing costs and timing mismatches affecting both manufacturing and research segments.
Full Analysis
Charles River Laboratories International (CRL) reported first-quarter 2026 financial results that align with or slightly exceed management's previous guidance while reaffirming its full-year outlook. The company reported total revenue of $996 million, a 1.2% increase year-over-year on a reported basis, though organic revenue declined by 1.5%, consistent with prior expectations of a low single-digit decline. Non-GAAP earnings per share decreased 12% to $2.06, and the non-GAAP operating margin fell 280 basis points to 16.3%. Management attributes these declines to specific factors including lower revenue from third-party non-human primate sources, timing of stock compensation expenses related to the CEO transition, and increased sourcing costs within the Discovery and Safety Assessment segment. The quarter featured mixed performance across business segments, with the Manufacturing division showing organic growth of 2.9% and an operating margin improvement to 25.9%, driven by gains in Microbial Solutions. Conversely, the Research Models and Services segment saw a 5.5% organic revenue drop due to lower sales of research models, while the Discovery and Safety Assessment unit posted a 1.4% organic decline. New CEO Birgit Girshick, who took office around the time of the earnings call, introduced a refreshed strategic framework titled "Pathway to Purpose," focusing on operational modernization and portfolio strengthening. The company completed the divestiture of its CDMO and Cell Solutions businesses and plans to sell certain European discovery sites later in May to refine its portfolio and improve margins. Guidance for the full year 2026 remains intact with projected organic revenue decline between 0.5% and 1.5%, and non-GAAP EPS of $10.80 to $11.30, representing a 5% to 10% growth over 2025 levels. Management expects operating margin expansion of approximately 120 to 150 basis points throughout the year, with significant improvement anticipated in the second half due to completed acquisitions, divestitures, and cost savings. Charles River also repurchased approximately $200 million in shares during the quarter under a $1 billion authorization, maintaining net leverage at 2.6 times. The company plans to provide further details on its strategy at an upcoming Investor Day in September.